Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332280 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HTR1AKCNH2 | |
| Maleic Acid SCHEMBL29410667 | 0.73 | SLC6A11 (0.49) | ALDH1A1KMT2AMEN1HTR1AKCNH2 | |
| SCHEMBL12204134 | 0.71 | PSMB1 (0.64) | TSHRALDH1A1KMT2ASIGMAR1MEN1 | |
| SCHEMBL24351544 | 0.70 | SIGMAR1 (0.70) | ALDH1A1KMT2ASIGMAR1HTR1AKCNH2 | |
| SCHEMBL25039185 | 0.70 | ALDH1A1 (0.55) | TSHRALDH1A1KMT2ASIGMAR1MEN1 | |
| SCHEMBL11487270 | 0.69 | ALDH1A1 (0.67) | TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL11492547 | 0.69 | ALDH1A1 (0.60) | TSHRALDH1A1KMT2ASIGMAR1MEN1 | |
| Difencloxazine SCHEMBL29710921 | 0.69 | SLC6A2 (0.76) | TSHRALDH1A1KMT2ASIGMAR1MEN1 | |
| SCHEMBL11245857 | 0.68 | ALDH1A1 (0.52) | TSHRALDH1A1KMT2ASIGMAR1HTR1A | |
| SCHEMBL1939359 | 0.68 | KMT2A (0.72) | ALDH1A1KMT2AMEN1HTR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | US | claimed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | claimed |
| WO-2002040018-A1 | TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON, INC. (CH) | 2002-05-23 | — | — | WO | claimed |
| WO-2002017930-A2 | GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD-BRAIN BARRIER PERMEABILITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-03-07 | — | — | WO | claimed |
| US-6177427-B1 | NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. | 2001-01-23 | — | — | US | claimed |
| EP-1047410-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 2000-11-02 | — | — | EP | claimed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | claimed |
| WO-1999032101-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | claimed |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| EP-2576582-B1 | TREATMENT OF MUSCULAR DYSTROPHY | CORCEPT THERAPEUTICS INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9782457-B2 | Flowable formulations for tissue repair and regeneration | TISSUE REPAIR COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| EP-1648439-B1 | ANTIGLUCOCORTICOID THERAPY FOR THE PREVENTION OF NEUROLOGICAL DAMAGE IN PREMATURE INFANTS | CORCEPT THERAPEUTICS INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8741880-B2 | Antiglucocorticoid therapy for the prevention of neurological damage in premature infants | CORCEPT THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | disclosed |
| WO-2002040018-A1 | TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON, INC. (CH) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002017930-A2 | GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD-BRAIN BARRIER PERMEABILITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6177427-B1 | NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. | 2001-01-23 | — | — | US | disclosed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CRHR2, IL2, GRIA2 | TSHR 193/4885ALDH1A1 3275/4885KMT2A 1145/4885 |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NR3C1, CRHR1, NR3C2 | TSHR 444/4885ALDH1A1 3297/4885KMT2A 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.